Stock DNA
Pharmaceuticals & Biotechnology
SEK 2,968 Million (Small Cap)
NA (Loss Making)
NA
0.00%
0.08
-15.27%
2.13
Revenue and Profits:
Net Sales:
92 Million
(Quarterly Results - Jun 2025)
Net Profit:
-37 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.06%
0%
-11.06%
6 Months
3.04%
0%
3.04%
1 Year
11.95%
0%
11.95%
2 Years
9.88%
0%
9.88%
3 Years
44.69%
0%
44.69%
4 Years
-55.84%
0%
-55.84%
5 Years
-54.13%
0%
-54.13%
Smart Eye AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
44.53%
EBIT Growth (5y)
-170.81%
EBIT to Interest (avg)
-134.27
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.05
Sales to Capital Employed (avg)
0.20
Tax Ratio
10.66%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.31
EV to EBIT
-14.70
EV to EBITDA
-63.71
EV to Capital Employed
2.22
EV to Sales
9.17
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-15.09%
ROE (Latest)
-15.27%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
92.10
89.60
2.79%
Operating Profit (PBDIT) excl Other Income
4.30
-23.10
118.61%
Interest
3.50
0.20
1,650.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-37.40
-54.20
31.00%
Operating Profit Margin (Excl OI)
-404.50%
-714.00%
30.95%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 2.79% vs 30.23% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 31.00% vs 20.99% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
355.00
302.20
17.47%
Operating Profit (PBDIT) excl Other Income
-82.70
-132.30
37.49%
Interest
4.40
2.30
91.30%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-230.40
-75.50
-205.17%
Operating Profit Margin (Excl OI)
-706.10%
-951.30%
24.52%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 17.47% vs 37.68% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -205.17% vs 77.81% in Dec 2023
About Smart Eye AB 
Smart Eye AB
Pharmaceuticals & Biotechnology
Smart Eye AB (publ) is a Sweden-based company engaged in the machine vision system development. The Company focuses on designing a real-time eyelid and head tracking technology. The Company's activities are divided into two areas: Applied solutions and Research instruments. The Applied solutions area offers tracking technology for automotive industry, including AntiSleep, an integrated camera and software, which measures driver head pose, gaze direction and eyelid closure, and Blackbird, a compact camera system for tracking and measuring human eye and head movements. The Research instruments area provides equipment for tracking, measuring and analyzing human eye movements in various industries, such as aerospace, aviation, psychology, communication, neuroscience, medicine and clinical research.
Company Coordinates 
Company Details
Forsta Langgatan 28B , GOTEBORG None : 413 27
Registrar Details






